BIIB

Biogen Inc. is a global biotechnology company pioneering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, Biogen has built a leading position in multiple sclerosis (MS) therapies and is advancing treatments for Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and other neurological conditions. The company combines deep scientific expertise in neuroscience, biologics development, and commercial capabilities to deliver transformative medicines addressing some of medicine's most challenging diseases. Biogen's commercial portfolio includes leading MS therapies such as Tecfidera, Tysabri, Vumerity, and Avonex, representing various mechanisms of action and delivery methods serving different patient needs. SPINRAZA, for spinal muscular atrophy, represents a breakthrough therapy addressing a previously untreatable genetic disease in children. The company received controversial FDA accelerated approval for Aduhelm (aducanumab) for early Alzheimer's disease, though commercial uptake has been limited. Biogen has subsequently focused on Leqembi (lecanemab), developed with partner Eisai, which received full FDA approval as an Alzheimer's treatment showing modest clinical benefit in slowing disease progression. Biogen's pipeline includes multiple neurological and neurodegenerative programs in various development stages. The company has established collaborations with leading research institutions and pharmaceutical partners including Eisai, Samsung Bioepis (biosimilars), and others. Biogen has faced headwinds including biosimilar competition eroding MS franchise revenues, challenges commercializing Alzheimer's therapies, and pipeline setbacks. The company has undertaken strategic reviews, cost reductions, and business development activities to offset revenue pressures and rebuild growth. Biogen's deep expertise in neuroscience, established commercial infrastructure, and continued R&D investments position it to remain significant in neurological disease treatment, though successfully launching growth products and navigating competitive and regulatory dynamics remain critical to long-term success.